These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28827416)

  • 1. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
    Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
    Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
    Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
    Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
    Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
    Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
    Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
    Frézard F; Michalick MS; Soares CF; Demicheli C
    Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
    Borborema SET; Osso Junior JA; Tempone AG; de Andrade Junior HF; do Nascimento N
    Biomed Pharmacother; 2018 Jul; 103():1609-1616. PubMed ID: 29864949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
    Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
    Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
    Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
    Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
    Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.
    da Silva SM; Amorim IF; Ribeiro RR; Azevedo EG; Demicheli C; Melo MN; Tafuri WL; Gontijo NF; Michalick MS; Frézard F
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2858-67. PubMed ID: 22411610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
    Moosavian SA; Fallah M; Jaafari MR
    Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Dullin M; Sulahian A; Garin YJ; Derouin F
    Antimicrob Agents Chemother; 1999 Jan; 43(1):172-4. PubMed ID: 9869587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
    Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
    Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
    Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
    Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavior of two Leishmania infantum strains-evaluation of susceptibility to antimonials and expression of microRNAs in experimentally infected J774 macrophages and in BALB/c mice.
    Silva SC; Silva DF; Almeida TC; Perasoli FB; da Silva ATP; da Silva GN; Rezende SA
    Parasitol Res; 2018 Sep; 117(9):2881-2893. PubMed ID: 29943317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.